Repligen Executive Chair Tony Hunt to Retire; Dr. Martin D. Madaus Named New Chair

Repligen Corporation, a leading life sciences company specializing in bioprocessing technologies, has announced a significant leadership transition. Tony Hunt, the current Executive Chair of the Board, has decided to retire, prompting the company’s Board of Directors to appoint Dr. Martin D. Madaus as the new Chair, effective immediately. This change marks an important moment for Repligen as it continues to advance its position in the bioprocessing industry.

Tony Hunt’s retirement comes after a notable tenure during which he contributed to Repligen’s growth and strategic direction. Under his leadership, the company strengthened its technological capabilities and expanded its market presence. His departure is seen as a planned and orderly transition, ensuring continuity in governance and strategic oversight.

Dr. Martin D. Madaus brings a wealth of experience to his new role as Chair of the Board. With a strong background in life sciences and corporate governance, Dr. Madaus is expected to provide steady leadership as Repligen navigates the evolving landscape of bioprocessing technology. His appointment reflects the Board’s confidence in his ability to guide the company through its next phase of development.

Repligen Corporation, traded on NASDAQ under the ticker RGEN, focuses on innovative bioprocessing solutions that support the production of biologic drugs. The company’s technologies are integral to improving the efficiency and scalability of biomanufacturing processes, which are critical in the pharmaceutical industry. Leadership stability is crucial for maintaining investor confidence and driving continued innovation.

This leadership change aligns with Repligen’s broader strategic goals of enhancing shareholder value and maintaining its competitive edge. The company’s Board emphasizes that Dr. Madaus’s appointment will help sustain the momentum built over recent years while positioning Repligen to capitalize on emerging opportunities in the bioprocessing sector.

In summary, Repligen’s transition in Board leadership marks a pivotal step in its corporate governance. Tony Hunt’s retirement and Dr. Martin D. Madaus’s elevation to Chair signal a commitment to continuity and strategic focus. Stakeholders can expect ongoing dedication to advancing bioprocessing technologies under this new leadership structure.